NASDAQ:INNL - (INNL) Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.35
+0.30 (1.20%)
Get New (INNL) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INNL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INNL

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for (INNL) in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.35.

This chart shows the closing price for INNL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in (INNL). This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/4/2017(FBRC)Reiterated RatingHoldLow
4/6/2017(FBRC)Reiterated RatingHoldLow
3/29/2017JMP SecuritiesUpgradeOutperform$4.00High
3/17/2017Stifel NicolausDowngradeBuy ➝ Hold$9.00 ➝ $2.00High
12/30/2016(FBRC)DowngradeOutperform ➝ Market Perform$2.00 ➝ $10.00N/A
12/30/2016JMP SecuritiesDowngradeOutperform ➝ Market PerformN/A
12/30/2016Janney Montgomery ScottDowngradeBuy ➝ Neutral$2.00N/A
11/6/2016JMP SecuritiesReiterated RatingBuyN/A
11/4/2016(FBRC)Lower Price TargetOutperform$18.00 ➝ $13.00N/A
6/30/2016(FBRC)Initiated CoverageOutperform$18.00N/A
(Data available from 6/21/2016 forward)
(INNL) logo
Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically. Using its processes at its manufacturing facility, it derives and purifies bovine and equine collagen and then utilizes its technology platform to incorporate the purified collagen into its topical and implantable products. Its lead product candidates are XaraColl for the treatment of post-operative pain and Cogenzia for the treatment of diabetic foot infections. Its marketed products include CollaGUARD, Collatamp, Septocoll and RegenePro. It has initiated its Phase III efficacy trials for Cogenzia.
Read More

Today's Range

Now: $2.35
Low: $2.35
High: $2.35

50 Day Range

MA: N/A

52 Week Range

Now: $2.35
Low: $0.53
High: $6.51

Volume

N/A

Average Volume

867,012 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of (INNL)?

The following equities research analysts have issued stock ratings on (INNL) in the last twelve months:
View the latest analyst ratings for INNL.

What is the current price target for (INNL)?

0 Wall Street analysts have set twelve-month price targets for (INNL) in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for (INNL) in the next year.
View the latest price targets for INNL.

What is the current consensus analyst rating for (INNL)?

(INNL) currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for INNL.

How do I contact (INNL)'s investor relations team?

(INNL)'s physical mailing address is Unit 9, Block D, Monksland Business Park, ATHLONE, NONE, Ireland. The specialty pharmaceutical company's listed phone number is +353-90-6486834. The official website for (INNL) is www.innocoll.com.